Ignite Creation Date:
2024-05-05 @ 10:59 PM
Last Modification Date:
2024-10-26 @ 10:26 AM
Study NCT ID:
NCT01222702
Status:
COMPLETED
Last Update Posted:
2017-06-14
First Post:
2010-10-08
Brief Title:
Efficacy Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea CDAD
Sponsor:
Actelion
Organization:
Actelion
Study Overview
Official Title:
A Multi-center Double-blind Randomized Active Reference Parallel Group Study to Evaluate the Efficacy Safety and Tolerability of a 10-day Twice Daily Oral Administration of Three Doses of Cadazolid ACT-179811 in Subjects With Clostridium Difficile Associated Diarrhea CDAD
Status:
COMPLETED
Status Verified Date:
2017-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cadazolid is a new antibiotic developed for the treatment of Clostridiun difficile associated diarrhea CDAD also known as Clostridium Difficile Infection CDI The purpose of the study was to evaluate the efficacy and safety of different doses of cadazolid in order to find the dose of cadazolid to be used for further clinical development of the compound in subjects with CDAD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None